DMP Stock Overview
Manufactures and sells off-patent branded pharmaceutical products in Germany. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 3/6 |
| Past Performance | 2/6 |
| Financial Health | 3/6 |
| Dividends | 3/6 |
Dermapharm Holding SE Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €37.90 |
| 52 Week High | €38.10 |
| 52 Week Low | €30.60 |
| Beta | 1.14 |
| 11 Month Change | 21.28% |
| 3 Month Change | n/a |
| 1 Year Change | n/a |
| 33 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | 8.60% |
Recent News & Updates
Recent updates
Shareholder Returns
| DMP | AT Pharmaceuticals | AT Market | |
|---|---|---|---|
| 7D | 10.5% | 3.3% | -0.1% |
| 1Y | n/a | 6.2% | 2.9% |
Return vs Industry: Insufficient data to determine how DMP performed against the Austrian Pharmaceuticals industry.
Return vs Market: Insufficient data to determine how DMP performed against the Austrian Market.
Price Volatility
| DMP volatility | |
|---|---|
| DMP Average Weekly Movement | 4.4% |
| Pharmaceuticals Industry Average Movement | 5.3% |
| Market Average Movement | 3.6% |
| 10% most volatile stocks in AT Market | 6.5% |
| 10% least volatile stocks in AT Market | 1.8% |
Stable Share Price: DMP has not had significant price volatility in the past 3 months compared to the Austrian market.
Volatility Over Time: Insufficient data to determine DMP's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1991 | 3,603 | Hans-Georg Feldmeier | ir.dermapharm.de |
Dermapharm Holding SE, together with its subsidiaries, manufactures and sells off-patent branded pharmaceutical products in Germany. The company operates through three segments: Branded Pharmaceuticals and Other Healthcare Products, Parallel Import Business, and Herbal Extracts. It offers branded generics, OTC products, non-prescription healthcare products, and herbal extracts and parallel-imported originator pharmaceuticals.
Dermapharm Holding SE Fundamentals Summary
| DMP fundamental statistics | |
|---|---|
| Market cap | €2.05b |
| Earnings (TTM) | €90.59m |
| Revenue (TTM) | €1.17b |
22.6x
P/E Ratio1.7x
P/S RatioIs DMP overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| DMP income statement (TTM) | |
|---|---|
| Revenue | €1.17b |
| Cost of Revenue | €439.61m |
| Gross Profit | €734.32m |
| Other Expenses | €643.74m |
| Earnings | €90.59m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
Mar 28, 2025
| Earnings per share (EPS) | 1.68 |
| Gross Margin | 62.55% |
| Net Profit Margin | 7.72% |
| Debt/Equity Ratio | 174.1% |
How did DMP perform over the long term?
See historical performance and comparison